BriaCell Therapeutics Announces Preclinical Data Presentation
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT), a pioneering clinical-stage biotechnology company, has exciting news regarding its innovative work in immunotherapy aimed at transforming cancer care. The company is thrilled to present its preclinical data on the promising Bria-OTS+ therapy at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting.
Details of the Presentation
This highly anticipated event will take place during the SITC 40th Anniversary Annual Meeting from November 7 to 9. BriaCell's presentation will focus on its research titled "Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance." This title aptly reflects the company’s commitment to enhancing cancer vaccine efficacy.
Event Information
Details of the poster presentation are as follows:
- Abstract Number: 353
- Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
- Date: Friday, November 7
Understanding Bria-OTS+
Bria-OTS+ represents one of BriaCell’s significant innovations, combining cutting-edge strategies in immunotherapy to tackle the complexities of cancer treatment. The therapy's focus on harnessing both innate and adaptive immune responses aims to create an effective, targeted approach to cancer vaccines, ultimately offering patients new hope in their treatment journey.
The Importance of Innovative Therapies
Cancer remains a leading global health challenge, and the quest for effective treatments continues to be at the forefront of medical research. With advancements in immunotherapy, tailored cancer vaccines like Bria-OTS+ have the potential to revolutionize how we approach cancer care. The upcoming SITC presentation provides an important platform to share these advancements and discuss their implications for future cancer treatments.
About BriaCell Therapeutics Corp.
As a clinical-stage biotechnology leader, BriaCell is focused on revolutionizing cancer therapy through novel immunotherapeutic approaches. The company emphasizes the integration of advanced science with compassionate patient care, designing therapies that aim to empower the immune system in its battle against cancer.
Contact Information for BriaCell
For more detailed inquiries or to learn more about BriaCell’s groundbreaking work, please feel free to reach out to the following contacts:
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
Frequently Asked Questions
What is Bria-OTS+?
Bria-OTS+ is an innovative cancer immunotherapy developed by BriaCell that integrates trained innate immunity and adaptive memory to fight against cancer effectively.
When will BriaCell present its data?
BriaCell will present its preclinical data on Bria-OTS+ at the SITC Annual Meeting from November 7 to 9.
Where can I find more information about BriaCell?
More information can be found on BriaCell's official website at briacell.com.
What is the significance of the SITC meeting?
The SITC meeting is a crucial event for sharing advancements in cancer immunotherapy, allowing researchers and practitioners to collaborate and discuss innovative therapies.
How can I contact BriaCell for inquiries?
You can reach BriaCell’s team via email at info@briacell.com for general inquiries or investors@briacell.com for investor relations.